Nice feature profile on CBSC. Thanks for the link. I especially like the coverage of the CB Scientific leadership team and it's high qualifications.
From the story:
Interesting to note, CB’s President and CEO Charles ‘Chip’ Martin worked as the Senior Director of Global Sales for BioTelemetry (BEAT) from 2015 to 2018. He’s back!
The company has secured US FDA 510K Registration through My-Cardia (USA) Inc. with authorizations for Singapore, Malaysia and Thailand.
The killer management team, is not just scientists – but also businessmen with exceptional sales and marketing experience. “No sales, no marketing, no business!” And these folks know how to sell!
Charles “Chip” Martin CEO, President and Director
He has held positions in sales, marketing, and executive management in the non-invasive Ambulatory ECG marketplace for more than 35 years. His career in the cardiac medical market began with Oxford Medical in 1985 where he sold the first “real-time” Holter analysis software system and recording devices offered in the US in a four-state Midwest territory.
He was promoted to Eastern Regional Sales Manager for the company in 1987. Career highlights include Regional Sales Manager for Spacelabs (Holter, Ambulatory Blood Pressure), National Sales Manager and Director of Sales for Instromedix (Cardiac Event Monitoring – King of Hearts), VP Sales and Marketing for CardioComm Solutions (GEMS Acquisition ECG Software for Event & Pacer TTM follow-up), and VP of Business Development with Biomedical Systems (IDTF Services, Holter, AEM, MCT).
From 2014 to 2018, Chip worked as the Senior Director of Global Sales for BioTelemetry Inc. a widely recognized leading provider of remote cardiac monitoring diagnostic services in the US that is publicly traded on the NASDAQ exchange (BEAT). He held the position of SVP of Sales and Marketing for My-Cardia (USA) Inc. from 2018 to 2019 and was promoted to CEO and President of Prevent Health Care International Corporation in August 2019, assuming the same roles now at CB Scientific, Inc., as well as Director.
Robert Kelley CFO, Vice President and Director
He has extensive experience with high-growth companies from VC-backed high-technology startups to large public corporations in roles including founder, CTO/VP Engineering, EVP Strategic Marketing, Corporate Development. He has led multiple first-mover product teams developing novel enterprise technologies from high-performance computers, broadband networks, and storage, to enterprise software from manufacturing/ERP, financial/accounting, and data warehousing/BI.
His graduate studies and teaching includes Computer Science, Linguistics and Artificial Intelligence, Marketing, and Analytics. Rob is a Chartered Financial Analyst (CFA). Rob uses analytics and his technology experience to inform marketing strategy, evaluate emerging technologies, and understand the economic value for customers.
James E. Ott Director
He held several senior leadership positions in his twenty-eight-year career in the Ambulatory ECG and Clinical Research Trials arena. Upon earning his Master of Science in Biomedical Engineering at Marquette University in 1991, Jim joined Biomedical System in St. Louis, MO in 1992 as a Product Manager where he coordinated the design, development and marketing efforts of their cardiac diagnostic software platform lines.
He was promoted in 2000 to President of Biomedical Systems Cardiology Division where he managed all aspects of their Independent Diagnostic Testing Facility (IDTF) to include international direct and distributor capital equipment sales, IDTF cardiology lab staffing, technology, sales and marketing, customer service, and reimbursement and regulatory activities.
During this time he managed the design, development, and implementation of the company’s internet-based Holter data and report transfer platform (Data Exchange), their internet-based Holter analysis platform (MyHolter.com), and their Mobile Cardiac Telemetry (MCT) platform – the TruVue® Wireless ECG Monitoring System. Jim was an integral part of successful US patent submissions and granted approvals for all three of these applications in 2004, 2005, and 2013 where he is listed as one of the inventors.
